EXTON, Pa.--(BUSINESS WIRE)--
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will report second quarter and first half 2014 financial and operating results on August 11, 2014. David Pernock, chairman and chief executive officer of Fibrocell Science, will host the conference call and webcast at 8:30 a.m. EDT, August 11, 2014.
The conference call may be accessed by dialing 855-877-0343 for domestic callers and 678-509-8772 for international callers. Please specify to the operator that you would like to join the "Fibrocell Science Second Quarter 2014 Financial Results Call, conference ID#: 72900123." The conference call will be webcast live under the investor relations section of Fibrocell's website at http://www.fibrocellscience.com/investors/events-and-presentations/, and will be archived there for 30 days following the call. Please visit Fibrocell's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NYSE MKT: FCSC) is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Based on its proprietary autologous fibroblast technology, Fibrocell is pursuing breakthrough medical applications of azficel-T for restrictive burn scarring and vocal cord scarring. The company’s collaboration with Intrexon Corporation (XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating orphan skin diseases for which there are no currently approved products. For additional information, visit www.fibrocellscience.com.
- Company Earnings
S.A. Noonan Communications, LLC
Susan Noonan, 212-966-3650